ATAT

Atour Lifestyle Holdings

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Consumer Cyclical

industry

Lodging

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/28/26

Business Summary

AngioDynamics develops and sells medical devices used in minimally invasive vascular and oncology procedures, generating revenue through hospital system sales and procedural adoption. Cash flow is driven by recurring usage of disposable devices once physicians integrate products into clinical workflows. The moat, where it exists, comes from regulatory approvals, physician training curves, and embedded hospital purchasing relationships rather than pricing power. However, sustained negative operating margins suggest that scale efficiencies and cost discipline—not product differentiation alone—will determine whether the business can convert clinical presence into durable free cash flow.

VALUATION

P/E

21.3

Market Cap ($M USD)

$4,992

Forward P/E

2

PEG

-

PRICE TO SALES

3.5

PRICE TO BOOK

9.5

EV / EBITDA

16.3

5-Year Average P/E

DIVIDEND

Yield

2.20%

Annual Payout

$0.78

Payout Ratio

28.60%

Consecutive Years of Dividend Growth

2

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$1.54

Next Year EPS Growth Estimate

$17.91

Next Year Revenue Growth Estimate

19.50%

Return on Equity (ROE)

39.80%

Operating Margin

22.20%

Debt-to-Equity

0.4

Piotroski F-Score

7

Altman Z-Score

6.5

Return on Invested Capital (ROIC)

27.60%%

Current Ratio

2.2

Quick Ratio

Gainseekers Quantitative Analysis

Summary

ANGO is a distressed small-cap healthcare name with a $404M market cap trading at 1.3x sales and 2.3x book, but the absence of both trailing and forward P/E combined with an Altman Z-Score of 1.7 puts it firmly in financial stress territory. Operating margin of -18.10% and ROIC of -18.00% confirm capital is being destroyed, not compounded. While the Piotroski F-Score of 6 suggests some internal stabilization, the balance sheet risk implied by the Z-Score overwhelms that signal. This is not a misunderstood growth story—it is a turnaround speculation where survival, not expansion, is the key variable.

AI Exposure / Tech Reliance

As a Medical Instruments & Supplies company within Healthcare, ANGO operates in a sector that increasingly integrates AI into imaging, diagnostics, and procedural optimization. Companies in this industry that adapt to AI-enhanced surgical planning and data-driven device performance can improve efficiency and margins over time. However, with current negative operating margins, ANGO must first stabilize its core economics before meaningfully capitalizing on tech-driven tailwinds.

The Bull Case

A deep value investor could argue the 1.3x Price/Sales and 2.3x Price/Book multiples already discount substantial pessimism for a healthcare device manufacturer. The Piotroski F-Score of 6 signals moderate fundamental stability, not deterioration, which is notable given the negative operating margin. Return on Equity at 4.80% is positive despite operating losses, suggesting some underlying capital efficiency pockets. A Current Ratio of 2.4 provides liquidity breathing room, and with a market cap of just $404M, even modest operational improvement could create outsized equity re-rating potential.

The Bear Case

The bear case is far more straightforward. Operating margin at -18.10% and ROIC at -18.00% show a business structurally failing to earn its cost of capital. Debt/Equity at -6.50% raises balance sheet quality concerns, while the Altman Z-Score of 1.7 signals elevated financial distress risk. EPS Next Year estimated at -$0.76 alongside negative Sales Growth Next Year of -$0.22 indicates no near-term earnings inflection. With no dividend, no yield support, and no forward valuation anchor, investors are left underwriting a turnaround without statistical evidence of one.

Market Sentiment & Smart Money

Short Interest %

4.00%

Analyst Consensus

1.3

Average Analyst Price Target

$49.11

Institutional Ownership %

78.40%

1-Year Beta

0.94

Insider Buying % (6 Mo)

6.00%%

Distance to 52-Week High

83.70%%

Distance to 52-Week Low

168.10%%